Cleveland Evans: Cultural quirks surface for Name of the Year candidates
The Name of the Year for 2024, according to the American Name Society, is “Ozempic," as in “Ozempic face,” “oat-zempic” and ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
This Wegovy user spent $5,000 on a new wardrobe after losing 80 pounds - and she's not alone
Tori Allen says she's thrilled to have lost 80 pounds since she went on Wegovy, one of the GLP-1 drugs that more and more people are using to treat diabetes or lose weight.
How to Use DSTs and 1031 Exchanges for Diversification
This hypothetical case study shows how an investor used Delaware statutory trusts (DSTs) to build a diversified 1031 DST ...
Five Steps to Answer Your Million-Dollar Retirement Question
Are you saving enough to live comfortably in retirement? Here are the steps you can take now to find out if you're on track ...
Pharma is hopeful about Trump's second term — here's what to expect for drugmakers
Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...
thedailyupside2h
Novo Nordisk May Have Another Blockbuster on its Hands
On Friday, the Danish pharma giant released the stellar results from a phase 1/2 trial for a once-weekly jab in its pipeline.